Combination treatment with cetuximab in advanced nasopharyngeal carcinoma patients: a meta-analysis

PURPOSE: Cetuximab, an anti-epidermal growth factor receptor monoclonal antibody, carries the potential for combination treatment against nasopharyngeal carcinoma (NPC). We conducted a meta-analysis to assess the possible benefits and safety between the combination treatment with cetuximab and conve...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Jia, Sun, Changling, Zhou, Min, Zhang, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452812/
https://www.ncbi.nlm.nih.gov/pubmed/31040691
http://dx.doi.org/10.2147/OTT.S193039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452812/
https://www.ncbi.nlm.nih.gov/pubmed/31040691
http://dx.doi.org/10.2147/OTT.S193039

Ejemplares similares